Cargando…

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF). Patients with IPF aged ≥40 years with fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maher, Toby M., Costabel, Ulrich, Glassberg, Marilyn K., Kondoh, Yasuhiro, Ogura, Takashi, Scholand, Mary Beth, Kardatzke, David, Howard, Monet, Olsson, Julie, Neighbors, Margaret, Belloni, Paula, Swigris, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859504/ https://www.ncbi.nlm.nih.gov/pubmed/33008934 http://dx.doi.org/10.1183/13993003.02442-2019

Ejemplares similares

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Lebrikizumab in the personalized management of asthma
por: Thomson, Neil C, et al.
Publicado: (2012)

Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire
por: Swigris, Jeffrey J., et al.
Publicado: (2020)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

The changing treatment landscape in idiopathic pulmonary fibrosis
por: Costabel, Ulrich
Publicado: (2015)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
por: Noble, Paul W., et al.
Publicado: (2016)

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
por: Austin, Cary D., et al.
Publicado: (2020)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics Concluding remarks
por: Costabel, Ulrich
Publicado: (2013)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
por: Okragly, Angela J., et al.
Publicado: (2023)

Transitions and touchpoints in idiopathic pulmonary fibrosis
por: Swigris, Jeffrey J
Publicado: (2018)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Prasse, Antje, et al.
Publicado: (2019)

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
por: Szefler, Stanley J., et al.
Publicado: (2022)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
por: Hanania, Nicola A, et al.
Publicado: (2015)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
por: Scheerens, H, et al.
Publicado: (2014)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2017)

Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis
por: Tashiro, Jun, et al.
Publicado: (2017)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype
por: Scholand, Mary Beth, et al.
Publicado: (2014)

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
por: Costabel, Ulrich, et al.
Publicado: (2018)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7cfqd1gum4h5bjb4ud8bnqom5i